A new clinical consensus statement moves cardiac CT from a specialist tool to a front-line test, and it sets clear expectations for how referrals, acquisitions, and reports should look.
1. Why this statement matters
The EACVI/ESC clinical consensus statement is written for the general cardiologist who orders the scan, which makes it a practical reference for the reader who interprets it.
Key points
- It is a joint document of the European Association of Cardiovascular Imaging (EACVI) and the ESC Council for Cardiology Practice, published as an official statement in the European Heart Journal.
- Its stated aim is to raise the confidence of non-imaging cardiologists in requesting cardiac computed tomography (CCT).
- Scope extends well past coronary disease to valvular disease, cardiomyopathies, cardiac masses, large-vessel disease, and adult congenital heart disease.
- Each clinical section is built the same way: indication, technical assessment, prognostic value, what the referral should contain, and how to read the report.
- For readers, the "what the referral should contain" sections are effectively a template for protocol selection and report tailoring.
2. Scanner technology and acquisition
The statement treats 64-slice CT as the minimum platform and frames newer hardware as a way to widen the pool of scannable patients.
Key points
- 64-slice systems are the floor, with temporal resolution as their main constraint.
- Dual-source CT (DSCT) and wide-detector scanners (>256 slices) improve temporal resolution and coverage per rotation.
- Photon-counting detector CT (PCD-CT) pairs high temporal resolution with spatial resolution down to about 0.2 mm, which matters most for calcium blooming and stent lumens.
- Core requirements are unchanged: a 5–10 s breath-hold, ECG synchronisation, an unenhanced scan for calcium scoring, and iodinated contrast for CCTA.
3. Patient preparation, heart-rate control, and dose
Image quality is decided before the scan starts, so the statement spells out contraindications, limiting factors, and a premedication menu (its Table 1).
Key points
- Contraindications include prior moderate or severe iodinated contrast reactions, asthma or atopy requiring treatment, pregnancy, renal impairment, and clinical instability.
- Patient factors that erode accuracy are high heart rate (target ≤60 bpm), heart-rate variability, obesity, and breathing artefact.
- Dose follows ALARA, with a typical mean effective dose near 3 mSv and <1 mSv achievable on current platforms.
- Dose-saving levers are prospective ECG triggering, high-pitch spiral acquisition, iterative and deep-learning reconstruction, better detector efficiency, and tube-current modulation.
| Agent (generic) | Brand · manufacturer | Statement regimen | Reader notes | US pricing* |
|---|---|---|---|---|
| Metoprolol tartrate (oral) | Lopressor; widely generic (multiple manufacturers) | 100 mg PO, 1 h before scan | Check BP, bronchospasm history, and AV conduction first | Low-cost generic; pricing varies |
| Metoprolol (IV) | Generic injection | 5–20 mg IV, 5–10 min before scan | Titrate in the scanner to the target rate | Institutional supply |
| Ivabradine | Corlanor · Amgen AMGN; Procoralan (EU) · Servier (no ticker, private) | 5–7.5 mg BID for 2–3 days | Useful when beta-blockers are contraindicated; requires sinus rhythm | Generic from roughly $45–56 via GoodRx |
| Nitroglycerin (sublingual) | Nitrostat · Viatris VTRS | 800 µg, 5 min before scan | Hold with PDE-5 inhibitor use, severe AS, or hypotension | Generic from roughly $9 via GoodRx |
*Pricing is time-sensitive (checked September 2026) and varies by pharmacy, plan, and region; confirm on GoodRx or the manufacturer site.
4. Post-processing toolkit
The statement lists the standard reconstructions and makes clear that axial source images remain the reference.
Key points
- Trans-axial images are the primary 2D dataset and the place to confirm any finding.
- Multiplanar reformation (MPR) displays the 3D volume in any plane.
- Curved MPR (cMPR) follows the vessel centreline for longitudinal and true cross-sectional views, and depends on an accurate centreline.
- Maximum intensity projection (MIP) highlights high-attenuation structures such as contrast and calcium.
- Volume rendering (VR) shows spatial relationships and is best for communication, not stenosis grading.
5. What CCT can evaluate
Coronary assessment is the core use, while chambers, valves, and great vessels are covered when other modalities fall short or when anatomy drives decisions.
Key points — coronaries
- Detects and classifies anomalous coronary origins.
- Grades stenosis presence, location, extent, and severity with a standard scale (statement Table 2: 0%, <25%, 25–49%, 50–69%, 70–99%, 100%).
- Classifies plaque as non-calcified, calcified, or partially calcified.
- Flags adverse plaque features: low-attenuation plaque, positive remodelling, spotty calcification, and the napkin-ring sign.
- Quantifies plaque burden with the AHA 16-segment model or SCCT segmentation.
Key points — chambers, valves, vessels
- CCT is not a first-line test for chamber size or function unless echocardiography or CMR is limited or contraindicated.
- Retrospective ECG gating gives LV and RV volumes, mass, and function that agree well with CMR, at a dose cost.
- Valve anatomy, leaflet thickening, and leaflet calcification are clearly shown.
- ECG-triggered scans give precise aortic measurements and detect atheroma, thrombus, intramural haematoma, penetrating ulcer, and dissection flaps.
- The left atrium, pulmonary veins, and pulmonary arteries to the subsegmental level are well shown.
6. Coronary calcium score and CAC-DRS
The statement places the coronary artery calcium score (CACS) firmly in asymptomatic risk stratification and warns against reading it as a stenosis test.
Key points — technique
- ECG-gated, non-contrast acquisition with a short breath-hold and dose <1.0 mSv.
- A calcified lesion is any area ≥1 mm² at ≥130 HU.
- Lesion score = area (mm²) × density weight, where the weight is set by peak attenuation (see chart).
Key points — prognosis
- CACS predicts cardiovascular events regardless of age, sex, or ethnicity, and adds to ESC SCORE and Framingham risk estimates.
- In the Heinz Nixdorf Recall (HNR) study, adding CACS to Framingham gave a net reclassification improvement of about 22%, moving roughly a quarter of intermediate-risk subjects down and about a fifth up.
- CACS = 0 carries much lower event rates and lets statin therapy be deferred in suitable patients.
- CACS >100 or ≥75th percentile for age and sex supports statin initiation in line with ACC/AHA practice.
- CACS = 0 does not exclude obstructive non-calcified disease, particularly in younger or symptomatic patients.
| Element | Content | Reader tip |
|---|---|---|
| Total score | Categories 0 · 1–99 · 100–299 · ≥300 | Map to CAC-DRS 0–3 |
| Percentile | Age-, sex- (and ideally ethnicity-) matched comparison | Name the reference database used |
| Distribution | Number of vessels involved (N0–N4) | Include left main involvement explicitly |
| Coding | "Category/N" format, e.g. CAC-DRS 2/N3 | Pair with a plain-language risk sentence |
7. CCTA in acute chest pain
For low-to-intermediate likelihood ACS, the statement endorses CCTA as a fast route to safe discharge or to targeted invasive care.
Key points — indications and protocol
- Candidates are low-to-intermediate likelihood patients, including those managed with the ESC 0h/1h and 0h/2h hs-troponin algorithms.
- A triple rule-out protocol covers pulmonary embolism and acute aortic syndrome in one acquisition, but it uses a different protocol and more contrast.
- The referral must state rule-out ACS versus triple rule-out, plus risk profile, symptoms, ECG, troponin, and tolerance of beta-blockers and nitrates.
- Readers should expect notes on likely quality limits: heavy calcium, irregular rhythm, and obesity.
Key points — evidence
- CT-STAT (16 EDs) cut time to diagnosis by 54% (2.9 h vs 6.3 h) and costs by 38% versus rest-stress MPI.
- ACRIN-PA and ROMICAT-II showed no excess MACE about one month after a CT-first strategy.
- In ROMICAT, no CAD meant no MACE over 2 years, while non-obstructive disease carried about 4% two-year MACE risk and warrants prevention.
- High-risk plaque was more common in ACS in ROMICAT-II and stayed an independent predictor after adjusting for ≥50% stenosis.
- RAPID-CTCA found faster diagnostic clarity with early CCTA but no improvement in 1-year clinical outcomes, so patient selection matters.
- Non-obstructive to mild CAD supports early discharge; more than moderate disease needs further risk stratification.
8. CCTA in chronic coronary syndrome
The statement frames CCTA as a safe first-line anatomical test in chronic coronary syndrome (CCS), in line with the 2024 ESC CCS Guidelines, and points to outcome gains that come mainly from better prevention.
Key points — diagnostic performance
- In PACIFIC, per-patient accuracy was 85% for PET, 77% for SPECT, 74% for CCTA, and 84% for hybrid PET-CCTA.
- CCTA performs especially well in women, finding both obstructive and non-obstructive atherosclerosis with better prognostic value than stress testing.
- CCTA alone cannot diagnose INOCA, which needs a functional test on top of anatomy.
Key points — outcome trials
- In the CONFIRM registry, ≥50% and ≥70% stenoses and proximal LAD or left main disease predicted death, and no CAD gave a 99.7% negative predictive value for near-term mortality.
- PROMISE (10,003 patients) found no outcome difference versus functional testing, but fewer non-obstructive invasive angiograms with CCTA (3.4% vs 4.3%).
- SCOT-HEART changed the diagnosis in 27% of patients and cut CHD death or MI at 5 years (2.3% vs 3.9%), driven by more preventive therapy.
- DISCHARGE (3,561 patients) showed CCTA non-inferior to invasive angiography for MACE at 3.5 years (2.1% vs 3.0%), with fewer major procedural complications (0.5% vs 1.9%).
- CONSERVE showed that CCTA-guided selective catheterisation reduced unneeded invasive procedures without harming outcomes.
- In ICONIC, drawn from about 25,000 patients, roughly two-thirds of those who later had ACS showed only non-obstructive disease at baseline.
9. Plaque: high-risk features and statins
The statement treats plaque phenotype as prognostic information worth reporting, while cautioning that a vulnerable-looking plaque is not destiny.
Key points
- In a PROMISE substudy of more than 4,000 patients, high-risk plaque (HRP) carried about 2.7-fold higher risk of death, MI, or unstable angina, rising to an adjusted HR of 4.31 in non-obstructive disease.
- In a SCOT-HEART substudy, CHD death or non-fatal MI was 4.1% with HRP versus 1.4% without (HR 3.01).
- In CONFIRM, about 40% of patients with HRP never had an ACS, since an additional trigger is needed for plaque to cause an event.
- In a serial-CCTA registry of 1,255 patients followed for 3.8 years, statin therapy slowed plaque progression, increased calcific conversion, and reduced new HRP features.
- Practical implication: report HRP on every study where it is present, because it shifts preventive intensity even when stenosis is mild.
10. Reporting with CAD-RADS 2.0
The statement adopts CAD-RADS 2.0 as the reporting language, pairing stenosis grade with plaque burden and modifiers.
| Descriptor | Definition | Practical use |
|---|---|---|
| P1 mild | CACS 1–100 or SIS ≤2 | Consider preventive therapy |
| P2 moderate | CACS 101–300 or SIS 3–4 | Preventive therapy |
| P3 severe | CACS 301–999 or SIS 5–7 | Aggressive prevention |
| P4 extensive | CACS >1000 or SIS ≥8 | Aggressive prevention |
| N | Non-diagnostic segment(s) | State which segments and why |
| HRP | ≥2 high-risk plaque features | Flag even with mild stenosis |
| I+ / I− / I± | Ischaemia by CT-FFR or CT perfusion | Use when a functional CT result is available |
| S · G | Stent · bypass graft present | Comment on evaluability |
| E | Exceptions: anomaly, dissection, aneurysm, ectasia, fistula | Describe the non-atherosclerotic finding |
SIS = segment involvement score. Use either CACS or a plaque-burden method consistently. Example code: CAD-RADS 4A/P2/HRP.
11. Beyond the coronaries
The later sections of the statement cover functional CT and non-coronary indications, which is where many general cardiologists are least sure what to request.
Key points
- CT perfusion and CT-derived FFR add a functional layer to intermediate stenoses, and the 2026 SCCT CT-FFR consensus standardises reading about 2 cm distal to the lesion.
- Dedicated sections cover CCTA after PCI and CABG, valve disease, cardiomyopathies, cardiac masses, large-vessel disease, and adult congenital heart disease.
- A closing section addresses extracardiac findings, which every reader must review and report.
- Readers should use the full text for protocol detail in these areas, because indications and acquisition settings differ from standard CCTA.
| Area | Typical clinical question | Acquisition/reporting reminder (general practice) |
|---|---|---|
| Revascularised patients | Graft patency; in-stent restenosis | Stent size and platform limit evaluability; use sharp kernels and use S/G modifiers |
| Valve disease | TAVI planning; prosthetic valve dysfunction; endocarditis complications | Systolic annular measurements; leaflet thickening and motion need multiphase data |
| Cardiomyopathies | Tissue characterisation when CMR is not possible | Late iodine enhancement and ECV need a delayed acquisition |
| Cardiac masses | Thrombus vs tumour; LAA thrombus before ablation or cardioversion | A delayed phase separates thrombus from slow flow |
| Large vessels | Aneurysm size; acute aortic syndrome; PE | ECG-gated aortic root measurements; report inner-to-inner or outer-to-outer consistently |
| Adult CHD | Complex anatomy, shunts, conduits | Tailor contrast timing to the circulation being studied |
Case vignette (fictional)
A 58-year-old woman with hypertension and dyslipidaemia reports exertional chest tightness for two months, with a normal resting ECG and normal echocardiogram.
Clinical likelihood is intermediate, and she has no contraindication to contrast.
Her resting heart rate is 74 bpm, so she receives oral metoprolol 100 mg an hour before the scan and sublingual nitroglycerin on the table, reaching 58 bpm.
The calcium score is 180 (P2), and CCTA shows a 70–79% stenosis in the proximal LAD made of partially calcified plaque with low attenuation and positive remodelling.
The report reads CAD-RADS 4A/P2/HRP, with a note on the proximal location and a recommendation for high-intensity statin therapy.
CT-FFR measured 2 cm distal to the lesion is 0.72, adding the I+ modifier.
She is referred for elective invasive angiography with the CT map in hand, and her preventive therapy is intensified regardless of the procedure's result.
Bottom line for the CCTA reader
The 2026 EACVI/ESC statement treats cardiac CT as a routine front-line test and expects readers to deliver more than a stenosis grade.
- Demand structured referrals that state the clinical question, rule-out versus triple rule-out, and premedication tolerance.
- Control heart rate to ≤60 bpm and keep dose ALARA, ideally below 3 mSv.
- Report CACS with CAC-DRS, and CCTA with the full CAD-RADS 2.0 code including P, HRP, and modifiers.
- Treat non-obstructive disease and HRP as prevention triggers, since that is where the outcome benefit in SCOT-HEART came from.
- Add functional CT for CAD-RADS 3–4A where it is available, and always review extracardiac structures.
References
- Implementation of cardiac computed tomography in everyday practice: a clinical consensus statement of the EACVI of the ESC and the ESC Council for Cardiology Practice. European Heart Journal, 2026 (advance article; doi:10.1093/eurheartj/ehag389).
- CAD-RADS 2.0 – 2022 Coronary Artery Disease – Reporting and Data System: SCCT/ACC/ACR/NASCI expert consensus document. Radiology: Cardiothoracic Imaging, 2022.
- 2024 ESC Guidelines for the management of chronic coronary syndromes. European Society of Cardiology.
- Scottish Computed Tomography of the HEART (SCOT-HEART) — trial summary. American College of Cardiology.
- DISCHARGE hailed as a big step forward for CTA in stable chest pain. TCTMD, 2022.
- Fractional flow reserve in coronary CT angiography — 2026 expert consensus document. Society of Cardiovascular Computed Tomography.
Further viewing
- CAD-RADS 2.0: What you need to know about the new reporting system — Society of Cardiovascular Computed Tomography (YouTube).
- Coronary Artery Calcium: A Peek Under the Hood — UT Southwestern Medical Center (YouTube).
About the figures: the statement is © The European Society of Cardiology 2026 with all rights reserved, so its figures are linked at the matching point in this review rather than reproduced; the three visuals shown here are original graphics drawn from the reported values. To embed the original figures, request reuse permission from Oxford University Press (journals.permissions@oup.com).
Physician education disclaimer: This article is a summary for healthcare professionals and does not replace the full consensus statement, applicable guidelines, local protocols, or individual clinical judgement; the case vignette is fictional.
Financial disclaimer: Manufacturer tickers and drug prices are given for identification only, are time-sensitive (checked September 2026), and are not investment or purchasing advice.
